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radical non-surgical management of carcinoma of the
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Summary The optimal radical non-surgical management of carcinoma of the oesophagus has yet to be determined. The combination of
high-dose radiotherapy with chemotherapy is being explored, particularly in North America. The MRC Upper GI Working Party has debated
the areas where there is scientific uncertainty and which clinical trials may be appropriate to undertake in the UK.
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The combination of radiation and chemotherapy given synchro-
nously in the management of solid tumours has been investigated
by many. For gastrointestinal tumours this approach looks
promising. The United Kingdom Coordinating Committee on
Cancer Research Study (UKCCCR) anal cancer trial demonstrated
that the addition of chemotherapy to radical radiotherapy
improved the level of local tumour control as shown by a 46%
reduction in the risk of local failure with a median follow-up of42
months (UKCCR Anal Cancer Trial Working Party, 1996).
Promising results have also been achieved in head and neck
tumours. An overview analysis by Munro (1995) identifying 54
published, randomized controlled clinical trials in head and neck
cancer suggested that chemotherapy given synchronously with
radiotherapy might provide the most promising therapeutic gain.
Data from other tumour sites are available that demonstrate
survival benefit by the combination of these two therapies given
together, but it is unclear whether the survival benefit has been
due to a synergistic effect between the radiotherapy and the
chemotherapy, as local control is not always improved.
The results of combined radiation-chemotherapy in man and
animals have been reviewed previously (Steel, 1988; Tannock,
1989). Clinical trials have identified a number of methodological
issues that limit interpretation. These include study design and the
choice ofnormal tissue end points. A detailed critique by Yarnold et
al (1990) sees arequirementtodefine therapeutic gain as well as clin-
ical usefulness before a combined radiation-chemotherapy regimen
can be deemed 'superior' to a radiotherapy regimen alone. They
recommend studies designed to measure both therapeutic gain within
the treatment volume (i.e. to define effect) and to record side-effects
outside the volume (i.e. to define usefulness). The simplest way to
achieve this is a three-armed trial comparing the standard dose of
radiotherapy with ahigherdose orwith the addition ofchemotherapy.
However, no trial ofradiation-chemotherapy has achieved this.
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So what is the role of radiation-chemotherapy in the manage-
ment of carcinoma of the oesophagus? Some groups, for example
the Princess Margaret Hospital (PMH) in Toronto, have been using
the combination of fluorouracil and mitomycin and radical radio-
therapy (Keane et al, 1985) for the management of carcinoma of
the oesophagus for some considerable time. There are well-
rehearsed arguments as to whether the addition of chemotherapy
to radiotherapy is simply sparing radiation dose and whether
similar effects could be achieved by radiation dose escalation, with
external beam or brachytherapy boost. In the PMH regimen
overall radiotherapy treatment time is also assumed to be impor-
tant as treatment is with 50-54 Gy/20 fractions in 28 days.
Two randomized trials appear in the literature. One from Brazil
(Araujo et al, 1991) randomized 59 patients with stage II
squamous carcinoma of the oesophagus to radiotherapy (50 Gy in
25 fractions) or radiation-chemotherapy (including fluorouracil,
mitomycin and bleomycin during radiotherapy). There was no
difference in median duration of response (8 months) or 5-year
survival (6% vs 16% respectively, P = 0.16), but this trial was far
too small to detect a clinically useful difference reliably. Acute
toxicities were more pronounced in the radiation-chemotherapy
arm. The other, later and larger, trial from the Intergroup in the
USA, however, suggested a positive benefit from radiation-
chemotherapy (Herokovic et al, 1992; al-Sarraf, 1997). This inter-
group trial has raised the intensity ofthe debate about the value of
radiation-chemotherapy. A total of 121 patients with Tl-T3
NO-N1 carcinomas ofthe oesophagus were randomized to receive
radiotherapy alone or radiotherapy with synchronous chemo-
therapy. The radiotherapy alone arm was treated with 64 Gy in 32
fractions over 6 '/2 weeks, whereas the combined treatment arm
was treated to a dose of 50 Gy in 25 fractions over 5 weeks.
Radiotherapy in this arm was combined with two cycles of
fluorouracil 1 g m-2 daily for 4 days and cisplatin 75 mg m-2 day 1,
for two cycles during radiotherapy, and two cycles of this
chemotherapy were attempted after the completion of radio-
therapy. The trial was closed following the results of a preplanned
interim analysis. There were no survivors in the radiotherapy arm
but 30% survived in the combined arm.
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IS RADIATION-CHEMOTHERAPY NOW
STANDARD TREATMENT FOR THE RADICAL
NON-SURGICAL MANAGEMENT OF CARCINOMA
OF THE OESOPHAGUS?
It is possible to argue this either way. One could accept this well-
conducted Intergroup phase III randomized study with a clear-cut
end point as the definitive answer. There was a large difference in
5-year survival. However, there was only a small difference in
median survival and a large difference in toxicity. The radio-
therapy arm achieved only 8.9 months median survival compared
with 12.5 months in the radiation-chemotherapy arm. In-field
relapses, as defined clinically, occurred in 31 patients in the radio-
therapy arm compared with 24 in the radiation-chemotherapy arm.
This is a modest improvement in local control with chemotherapy
but was achieved at the expense of toxicity. Grade 4 toxicity
occurred in 20% of patients in the radiation-chemotherapy arm
compared with 3% in the radiotherapy arm. Two toxic deaths
occurred in the combined arm and only 50% ofpatients completed
the post-radiotherapy chemotherapy.
The trial was stopped prematurely with small numbers in
each arm and there are differences between the patient groups
treated in both arms. In the radiotherapy-alone group there are
more patients with more advanced stage disease, whereas more
patients in the combined arm had adenocarcinoma. Certainly no
useful information is provided in the study about the uncertainty
surrounding their estimates of treatment effect, although they do
give 95% confidence intervals for 2-year survival. From analysis
of their published results a hazard ratio of 0.47 for the treatment
difference is likely, which corresponds to a 24% increase in 2-year
survival. However, the confidence interval spans a range from
a 9% increase to a 38% increase - and both these extremes
are equally likely. Also, the authors of the study reveal that it
took 4 years to recruit 120 patients, in which time probably 40 000
new oesophageal cancers were diagnosed. It may therefore be
risky to extrapolate these results to 'standard' practice and it would
certainly be difficult to recommend this as routine
treatment when a 'cost-benefit' analysis is based on such a
wide range of possible treatment results. Some statisticians
and clinical triallists would prefer an approach to interim
analyses that is more flexible and pragmatic to the stopping
rules used in the Herskovic trial, formally and informally taking
into account the degree of 'scepticism' prevalent at the time of a
trial. A so-called Bayesian approach to monitoring trials (Parmar
et al 1994) may become more useful - indeed on review of the
meta-analysis of Bhansali et al (1996) the Herskovic trial is
certainly an outlier.
The Americans are now comparing their combined treatment
using 50 Gy/25 fractions and extended fields with higher doses of
radiotherapy, 64 Gy to a smaller volume combined with the same
chemotherapy in each arm. The question that they will attempt to
answer is whether increasing the dose ofradiotherapy to a smaller
volume when combined with chemotherapy increases survival. We
await the outcome ofthis trial.
Options to improve local control and survival
If one priority is to improve local control and survival for patients
unsuitable for surgery but suitable for radical radiotherapy, what
are the options?
OPTIMIZATION OF RADIATION THERAPY
A number ofapproaches are available to optimize radical radiation
therapy.
Decrease in overall radiotherapy treatment time
There is much evidence emerging that for some tumours overall
radiotherapy treatment time is important in achieving local control
because of repopulation of tumour cells during treatment. In the
Herskovic study the radiotherapy arm was given 64 Gy in 6 1/2
weeks. Many would argue for a shortened overall treatment time,
e.g. 54 Gy in 20 fractions over 4 weeks. In the recently completed
CHART (continuous hyper-fractionated accelerated radiotherapy)
study, in which treatment was given over 12 days (Saunders et al,
1996, 1997), one ofthe main conclusions was that overall treatment
time was shown to be important with respect to survival in the
management of squamous carcinomas ofthe bronchus (Saunders et
al, 1997). Perhaps future investigational therapy should involve a
shorter overall treatment time for carcinoma ofthe oesophagus and
indeed CHART for oesophageal carcinoma is currently being
investigated (Powell et al, 1997). If we feel that there is evidence
that overall treatment time is important, we must ensure when we
are devising investigational radiation-chemotherapy regimens that
we do not add chemotherapy and then need to extend overall radio-
therapy treatment time to overcome toxicity.
Increase the dose of radiotherapy
Ifthere is a dose-response relationship forradiotherapy then should
we increase the dose of radiotherapy and thereby increase tumour
control? Ways to increase the dose above standard doses are to (i)
use a brachytherapy boost (this is currently being considered by
some trial groups), or (ii) use conformal planning and thereby allow
dose escalation by minimizing normal tissue toxicity (in the case of
the oesophagus the dose limiting normal tissue will be the spinal
cord and lung) or (iii) alter fractionation such as using hyperfrac-
tionation to increase overall dose while sparing normal tissue.
Using radical dose external beam radiotherapy, we may be
working very close to radiation tolerance with limited room for
manoeuvre before major toxicity is encountered. However, at least
two randomized trials of brachytherapy boost treatment with
external beam have shown survival advantage (Flores, 1992; Yin,
1989). This does suggest a radiation dose response that probably
passes through the 60 Gy in 6 weeks watershed. Perhaps the intro-
duction of a mucosal protection agent, e.g. Ethyol, may allow
further dose escalation.
WHAT IS THE ROLE OF CHEMOTHERAPY?
Concomitant chemotherapy to increase local control
The mechanism for this synergy between radiotherapy and
chemotherapy is unclear, be it true radiosensitization or simply
additional cell kill. The regimens that have been used clinically in
combination therapy often give only one or two cycles of
chemotherapy treatment. It is difficult to suppose that these regi-
mens, which only have partial response rates in the region of
20-30%, will produce significant log cell kill with two cycles, and
so probably the most convincing hypothesis is that some radiosen-
sitization could be occurring. Any attempt at achieving a survival
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advantage from adjuvant or neoadjuvant chemotherapy is there-
fore likely to be unsuccessful, but there may be therapeutic gains
in the area of synchronous treatment. The Trans Tasman Radiation
Oncology Group (TROG) has analysed its unrandomized experi-
ence with radiation-chemotherapy in oesophageal cancer in 373
patients. It focused attention on chemotoxicity of combined
radiation-chemotherapy and found that the relationship between
fluorouracil dose and myelotoxicity is steep (McKean et al, 1996).
Importantly, the group found no indication that the relationship
between fluorouracil dose and efficacy is also steep (McKean et al,
1996), and indications of a radiation dose-response relationship
also emerged (Denham et al, 1996). These data suggest that we
should be careful with the dose of chemotherapy. Increasing
chemotherapy a little may increase the toxicity a lot and great care
should be taken not to compromise a radical radiotherapy dose by
the addition of chemotherapy. The addition of chemotherapy to
suboptimal radiotherapy proves nothing except perhaps to
demonstrate some mediocre activity for chemotherapy if the trial
radiotherapy arms are equivalent.
Timing ofconcomitant chemotherapy
Data on the optimal timing of chemotherapy with radiotherapy are
limited. It is not clear when any radiosensitizing effect may occur
and it may be several hours before or after the radiotherapy (Steel,
1997). One obvious way of getting round this uncertainty is to
treat with chemotherapy continuously during radiotherapy. Lokich
et al (1987) treated 13 patients in a phase II study with continuous
infusion of fluorouracil for 6 weeks before radiotherapy and then
in combination with 50-60 Gy of radiotherapy. The combination
was reasonably well tolerated with no significant bone marrow
toxicity and only two patients developed grade 3 oesophagitis.
However, a 15% central line thrombosis rate was evident. Poplin
et al (1994) added cisplatin to this continuous infusion to a dose of
25 mg m-2 x 3, weeks 1 and 3. The dose of radiotherapy was
between 40 and 50 Gy. Complete responders went on to receive
three cycles of chemotherapy afterwards. The message was clear
in this trial that the addition of platinum to the fluorouracil
regimen was too toxic. The central line thrombosis rate went up to
30%, 73% patients required hospitalization, 38% developed grade
3 leukopenia, 5% grade 4 leukopenia and thrombocytopenia, and
58% required a dose reduction or delay.
Which chemotherapeutic agents?
Initial studies with radiation chemotherapy involved fluorouracil
and mitomycin. Is the mitomycin important? In the UKCCCR anal
trial this combination proved the effective one. Interestingly, one
study compared this combination with one dropping the mito-
mycin for anal carcinoma (Flam et al, 1996) and a difference was
seen in local control. Mitomycin may be important in its radio-
sensitizing effect, perhaps because of its effect on hypoxic cells.
More recent studies, however, have used fluorouracil and
cisplatin combinations, particularly in the management of carci-
noma of the oesophagus. It is tempting to add platinum to the
fluorouracil-mitomycin combination. The MRC OE03 study
piloted such a regimen using radiotherapy to a dose of 52 Gy/20
fractions/28 days with mitomycin 6 mg m-2 day 1, cisplatin 60 mg
m-2 day 1 and 21 and fluorouracil 750 mg m-2 days 1-4 and 21-28.
It is an open question what is the most effective regimen. Cisplatin
may well be as effective as mitomycin, although it is not a biore-
ductive agent. There are more novel ways ofdelivering fluorouracil
as either a prolonged venous infusion (PVI) providing fluorouracil
continuously throughout treatment, or in combination with its
biochemical modulator, folinic acid. New chemotherapy agents
may be promising, such as paclitaxel and gemcytabine. It is diffi-
cult to anticipate which will provide the most effective and least
toxic combination.
Concomitant chemotherapy in the preoperative setting
Other data exist for the tolerability of chemotherapy with radio-
therapy from the preoperative setting. There are at least 38 phase II
studies now of radiation-chemotherapy in the preoperative situa-
tion, and response rate and toxicity have been well recorded. What
is becoming clear is that if the number of chemotherapy agents is
increased or their dose increased, the severity of toxicity increases
significantly.
'Adjuvant' chemotherapy to treat micrometastatic
disease
The use of adjuvant chemotherapy after primary conservative
management with radiation-chemotherapy has been attempted. In
the Intergroup trial (Herskovic et al, 1992) only 50% of the
patients managed to complete two cycles of chemotherapy post
treatment. Adjuvant therapy may be difficult in this disease. A
recent meta-analysis by Bhansali et al (1996) of 12 randomized
clinical trials and eight with historical controls revealed no
significant survival benefit from cisplatin-based adjuvant/
neoadjuvant chemotherapy in oesophageal cancer.
Neoadjuvant chemotherapy
Chemotherapy given before the main therapy of radiation-
chemotherapy has been studied. On a practical level, clinicians are
enthusiastic that an initial good response to chemotherapy may
improve dysphagia rapidly and may select those patients in whom
chemotherapy should continue to be used. Minsky et al (1996)
attempted three cycles of fluorouracil and cisplatin before radia-
tion-chemotherapy. The three cycles of fluorouracil and cisplatin
resulted in 61% ofgrade 3 toxicity. A total of9%1 % of patients went
on to complete the radiation-chemotherapy (radiation dose
64.8 Gy) with two cycles of fluorouracil and cisplatin; however,
six patients died with neutropenic sepsis and this treatment
approach has been abandoned. The advantage that a neoadjuvant
approach may induce an improvement in dysphagia early on may
be offset by toxicity compromising primary treatment. Also, if
there is accelerated repopulation in oesophageal cancer this
approach may compromise overall local control.
TRANSLATION OF RADIATION-CHEMOTHERAPY
TO THE PREOPERATIVE SETTING
Some of the arguments for optimal primary therapy can be trans-
ferred to the preoperative setting. Does preoperative chemotherapy
orradiotherapy orboth improve the survival or operability in patients
treated with surgery for localized oesophageal cancer? The MRC
OE02 study is near completion and is comparing surgery alone with
surgery plus two cycles of preoperative chemotherapy with fluoro-
uracil and cisplatin. A recent study from Ireland (Walsh et al, 1996)
suggested that the combination of radiotherapy plus chemotherapy
improved survival in patients with resectable adenocarcinoma ofthe
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oesophagus. Some argue that with an increasing incidence ofadeno-
carcinoma ofthe oesophagus, radiation-chemotherapy may become
increasingly important.
CONCLUSIONS
Radiation-chemotherapy has not yet been established as standard
therapy for the radical non-surgical management of carcinoma of
the oesophagus in the UK, although it has in other countries. In the
UK this may be due to reasons of scientific uncertainty, inexperi-
ence with combinations or lack of resources. Perhaps we are
reaching our limit with the current chemotherapy regimens and
radiation strategies. New agents and new approaches are needed
and we await eagerly the results ofthe ongoing randomized trials.
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